Nature Cell
-
East Asia
JointStem: A Road Closed by Korea’s MFDS, Now Opening in the United States
By Lee Sang-kiAsiaN reporter, former president of the Korea Journalists Association SEOUL: Nature Cell, a leading Korean biotech company, is accelerating its entry into the U.S. market with its stem cell therapy, JointStem. On the surface, this is a global expansion strategy, but beneath it lies a stark reality: the…
Read More » -
East Asia
Success of JointStem Phase 3 Clinical Trial, world’s first adipose tissue derived mesenchymal stem cell treatment for osteoarthritis of the knee
-Successful data for the reduction of pain and the improvement of knee cartilage function in severe osteoarthritis (OA) patients with Kellgren and Lawrence (K-L) grade 3 -The outcome of Korean stem cell research and development of 16 years and the results of hard work including tens of millions of dollars…
Read More »